The largest database of trusted experimental protocols

12 protocols using kpl trueblue peroxidase substrate

1

Quantifying SARS-CoV-2 Variant Titers

Check if the same lab product or an alternative is used in the 5 most similar protocols
Plaque assays were performed to determine viral titers in lungs from hamsters challenged with USA-WA1/2020, Alpha, Beta, Delta or Mu variants. Briefly, lungs were harvested from the animals and the cranial and middle lobes from the right lung were collected and homogenized in sterile 1x PBS for viral titration. Centrifugation was performed at 7,000 g for 5 minutes to remove tissue debris. Then, the homogenates were 10-fold serially diluted starting from a 1:10 dilution in 1x PBS. Pre-seeded Vero-E6/TMPRSS2 cells were infected with diluted lung homogenates for 1 hour at RT with occasional shaking, followed by an overlay of 2% oxoid agar mixed with 2x MEM supplemented with 0.3% FBS. The plates were incubated for 72 hours at 37°C and 5% CO2 followed by fixation in 1mL of 10% methanol-free formaldehyde. The plaques were immuno-stained with anti-mouse SARS-CoV-2-N antibody diluted 1:1000 in 1x PBST for 1.5 hr at RT with gentle shaking and subsequently with 1:5000 diluted HRP-conjugated anti-mouse secondary IgG antibody for 1 hr at RT. Finally, the plaques were developed with KPL TrueBlue Peroxidase Substrate (Seracare) and viral titers were calculated and represented as plaque forming units (PFU)/mL.
+ Open protocol
+ Expand
2

Evaluating Antiviral Priming and Infection

Check if the same lab product or an alternative is used in the 5 most similar protocols
The culture supernatants from mutant or WT EMCV-infected NHLFs or RIG-I KO HEK293 cells were UV-inactivated in a biosafety cabinet under a UV-C lamp (30W) at a dose of 5,000 μJ/cm2 for 15 min. Complete inactivation of EMCV was confirmed by plaque assay on BHK-21 cells. The inactivated supernatants were then transferred onto fresh Vero cells for 24 h, and the primed Vero cells were subsequently infected with ZIKV (MOI 0.002 to 2) for 72 h, or with EMCV (MOI 0.001 to 0.1) for 40 h. ZIKV-positive cells were determined by immunostaining with anti-flavivirus E antibody (4G2) and visualized using the KPL TrueBlue peroxidase substrate (SeraCare). EMCV-induced cytopathic effect was visualized by Coomassie blue staining.
+ Open protocol
+ Expand
3

Virus Quantification Assays for Flaviviruses

Check if the same lab product or an alternative is used in the 5 most similar protocols
crystal violet-based plaque assay was performed to quantify WNVKunjin and ZIKV, and immunofocus plaque assay was performed to quantify LGTV, TBEVSojin, KFDV, and POWV. In brief, a series of virus dilutions in DMEM were used to infect 90% confluent Vero cells for 1 h at 37°C, followed by cell-overlaying with DMEM supplemented with 1.2% Avicel (FMC), 2% HI–FBS (Gibco), 1× nonessential amino acids (Gibco), and 1% PEST (Gibco). After 3–5 days, the overlays were removed, and cells were fixed by methanol for 20 min before staining. For immunofocus assay, the fixed cells were blocked by 2% BSA (Fitzgerald) for 10 min before labeled with 1:1000 the mouse anti-E antibody, followed by 1:100 the anti-mouse secondary HRP Polymer for 1 h at 37°C. Finally, they were reacted with KPL TrueBlue Peroxidase Substrate (Seracare) for 15 min at room temperature (RT). For crystal violet-based plaque assay, the fixed cells were stained with 2% crystal violet (Sigma), 20% methanol (Fisher), and 0.1% ammonium oxalate (Sigma) solution.
+ Open protocol
+ Expand
4

Viral Titer Quantification for SARS-CoV-2 Variants

Check if the same lab product or an alternative is used in the 5 most similar protocols
Plaque assays were performed to determine viral titers in lungs from hamsters challenged with USA-WA1/2020, Alpha, Beta, Delta or Mu variants. Briefly, lungs were harvested from the animals and the cranial and middle lobes from the right lung were collected and homogenized in sterile 1x PBS for viral titration. Centrifugation was performed at 7,000 g for 5 minutes to remove tissue debris. Then, the homogenates were 10-fold serially diluted starting from a 1:10 dilution in 1x PBS. Pre-seeded Vero-E6/TMPRSS2 cells were infected with diluted lung homogenates for 1 hour at RT with occasional shaking, followed by an overlay of 2% oxoid agar mixed with 2x MEM supplemented with 0.3% FBS. The plates were incubated for 72 hours at 37°C and 5% CO2 followed by fixation in 1mL of 10% methanol-free formaldehyde. The plaques were immuno-stained with anti-mouse SARS-CoV-2-N antibody diluted 1:1000 in 1x PBST for 1.5 hr at RT with gentle shaking and subsequently with 1:5000 diluted HRP-conjugated anti-mouse secondary IgG antibody for 1 hr at RT. Finally, the plaques were developed with KPL TrueBlue Peroxidase Substrate (Seracare) and viral titers were calculated and represented as plaque forming units (PFU)/mL.
+ Open protocol
+ Expand
5

SARS-CoV-2 Plaque Assay Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
A SARS-CoV-2 strain (GISAID# EPI_ISL_425177) was received from the Vaccine and Infectious Disease Organization at the University of Saskatchewan and used as a positive control and plaque reference. Like the clinical isolates described in this report, this strain formed plaques that exhibited a halo-like appearance on Vero CCL-81 cells under a CMC overlay. To further confirm the identity of a subset of virus isolates, the fixed and strained plates were de-stained with ethanol and then immunostained with a 1:500 diluted rabbit anti-SARS-CoV-2 spike antibody (ProSci). The plaques were then visualized with a 2° goat anti-rabbit IgG antibody conjugated to horseradish peroxidase (Invitrogen) and a KPL TrueBlue peroxidase substrate (SeraCare).
+ Open protocol
+ Expand
6

SARS-CoV-2 Plaque Assay in Vero-E6 Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Confluent monolayers of Vero-E6 cells in 12-well plate format were infected with tenfold serially diluted samples in 1X phosphate-buffered saline (PBS pH 7.0; Corning 21040CV) supplemented with bovine serum albumin (BSA; MP-Bio 810063) and penicillin–streptomycin for an hour while gently shaking the plates every 15 min. Afterwards, the inoculum was removed, and the cells were incubated with an overlay composed of MEM with 2% FBS and 0.05% purified agar (OXOID-UK; LP0028) for 72 h at 37 °C with 5% CO2. The plates were subsequently fixed using 4% formaldehyde overnight and the formaldehyde was removed along with the overlay. Fixed monolayers were blocked with 5% milk in Tris-buffered saline with 0.1% tween-20 (TBS-T) for an hour. Afterwards, plates were immunostained using a monoclonal antibody cocktail against SARS-CoV-2 Spike (Creative-Biolabs; 2BCE5) and SARS-CoV-2 nucleocapsid protein NP (Creative-Biolabs; NP1C7C7) at a dilution of 1:1000 followed by 1:5000 anti-mouse IgG monoclonal antibody and was developed using KPL TrueBlue peroxidase substrate for 10 min (Seracare; 5510-0030). After washing the plates with distilled water, the number of plaques were counted. Data shown here is derived from three independent experimental setups. EMCV samples were processed in VERO-CCL81 cells in 6 well format, incubated for 48 h, and developed with crystal-violet.
+ Open protocol
+ Expand
7

Quantifying Virus Infectivity Titers

Check if the same lab product or an alternative is used in the 5 most similar protocols
crystal violet-based plaque assays were performed to quantify infectious WNVKUN and ZIKV particles, while immuno-focus plaque assays were performed to quantify infectious LGTV. In brief, series of virus dilutions in DMEM were used to infect 90% confluent Vero cells for 1 h at 37 °C, followed by cell-overlaying with DMEM supplemented with 1.2% Avicel (FMC, Philadelphia, PA, USA), 2% HI‒FBS, 1X NEAA, 1% PEST. After 3–4 days, the overlays were removed, and cells were fixed with methanol for 20 min before performing plaque assays. For immuno-focus assay, the fixed cells were blocked by 2% BSA for 10 min before being labeled with 1:1000 mouse LGTV E, then 1:100 VisUCyte anti-mouse secondary HRP Polymer for 1 h at 37 °C, respectively. Finally, the cells were incubated with KPL TrueBlue Peroxidase Substrate (Seracare, Milford, MA, USA) for 20 min at room temperature (RT). For crystal violet-based plaque assay, the fixed cells were stained with 1% crystal violet (Sigma), 20% methanol (Fisher, Trinidad and Tobago), and 1% ammonium oxalate (Sigma) solution.
+ Open protocol
+ Expand
8

Quantification of ILHV Virus via Focus Forming Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
ILHV was quantified via the focus forming assay. Briefly, virus was serially diluted in Vero maintenance media (MEM supplemented with 2% FBS and 1% each of GlutaMax (Gibco, Grand Island, NY), PenStrep, and sodium bicarbonate and inoculated onto 12-well plates of Vero cells. Virus was allowed to infect for 1 h in a 37 °C, 5% CO2 incubator. Following this incubation, an overlay of Opti-MEM (Gibco, Grand Island, NY) supplemented with 2% FBS, 1% PenStrep, and 1% carboxymethylcellulose (Sigma, St Louis, MO) was added to the wells and the plates were returned to the 37 °C, 5% CO2 incubator. After three days, the plates were fixed with 10% buffered formalin. Fixed plates were blocked with 5% non-fat milk in phosphate buffered saline (PBS, Sigma, St Louis, MO). Anti-ILHV mouse immune ascitic fluid (WRCEVA, Galveston, TX) was diluted 1:1000 in blocking buffer and allowed to bind to the fixed monolayers. Plates were washed with PBS, and HRP-conjugated goat anti-mouse IgG secondary antibody (KPL, Gaithersburg, MD) was diluted 1:2000 in blocking buffer and allowed to bind. Plates were subjected to a final set of washes and developed using KPL TrueBlue peroxidase substrate (SeraCare, Milford, MA).
+ Open protocol
+ Expand
9

Evaluating Antiviral Priming and Infection

Check if the same lab product or an alternative is used in the 5 most similar protocols
The culture supernatants from mutant or WT EMCV-infected NHLFs or RIG-I KO HEK293 cells were UV-inactivated in a biosafety cabinet under a UV-C lamp (30W) at a dose of 5,000 μJ/cm2 for 15 min. Complete inactivation of EMCV was confirmed by plaque assay on BHK-21 cells. The inactivated supernatants were then transferred onto fresh Vero cells for 24 h, and the primed Vero cells were subsequently infected with ZIKV (MOI 0.002 to 2) for 72 h, or with EMCV (MOI 0.001 to 0.1) for 40 h. ZIKV-positive cells were determined by immunostaining with anti-flavivirus E antibody (4G2) and visualized using the KPL TrueBlue peroxidase substrate (SeraCare). EMCV-induced cytopathic effect was visualized by Coomassie blue staining.
+ Open protocol
+ Expand
10

Viral Load Quantification in Mouse Lungs

Check if the same lab product or an alternative is used in the 5 most similar protocols
For determination of viral load in mouse lung tissues a standard plaque assay was performed. Confluent monolayers of MDCK cells were infected with serial dilutions of homogenized lung tissue ranging from 1:10 to 1:1,000,000 diluted in 1X MEM (1% penicillin–streptomycin antibiotics mix, 1% HEPES, 1% l-glutamine and 1% sodium-bicarbonate (Gibco)) for 1 h at 33 °C, with shaking every 15 min. Afterwards, an overlay containing 2% Oxoid agar (Thermo Fisher), H2O, 2X MEM, DEAE and TPCK-treated trypsin was added to the cells. The plates were incubated at 33 °C for 3 days and then fixed with 3.7% paraformaldehyde overnight at 4 °C. Plaques were visualized by immunostaining. Here, the agar overlay was removed and the plates blocked with 3% milk and PBS. The blocking solution was removed and primary antibody ((H1N1 guinea pig anti-sera (generated in house)) diluted 1:3,000 in 1% milk and PBS was added for 1 h. The plates were washed three times with PBS and secondary antibody (anti-mouse IgG H&L peroxidase-conjugated (Rockland) diluted 1:3,000 in 1% milk and PBS was added for 1 h. The plates were washed three times with PBS and developed by using KPL TrueBlue Peroxidase Substrate (SeraCare).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!